retatrutide peptide obesity triple hormone receptor agonist Medscape | Retatrutide, an investigational that shows promise for weight loss in ongoing phase-3 clinical trials, is Investigational Triple-G Injectable Scores Two
Pay in 4 interest-free payments of $5.64 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
























